(Reuters) -AbbVie expects Botox's market share in the aesthetics space to remain strong even as rivals launch competing anti-wrinkle injections, a company executive said on Wednesday. Botox sales, especially for aesthetic use, have been under pressure over the last few quarters due to economic uncertainties. Investors have also been concerned about potential market share losses to new entrants such as Revance Therapeutics' Daxxify and Evolus' Jeuveau.